
Pulled from Benzinga Pro data, Pacira BioSciences (NASDAQ:PCRX) posted Q1 earnings of $6.83 million, an increase from Q4 of 233.1%. Sales dropped to $157.99 million, a 0.76% decrease between quarters. In Q4, Pacira BioSciences brought in $159.19 million in sales but lost $5.13 million in earnings.